Presbia PLC Appoints Gerald Farrell, Ph.D. To The Board Of Directors

DUBLIN--(BUSINESS WIRE)--The Board of Directors of Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration, announced today that it has appointed Gerald Farrell, Ph.D. to serve on its Board of Directors and as a member of its Audit Committee.

Dr. Farrell has been involved in the pharmaceutical industry for more than 25 years, and worked for Eli Lilly Company Limited in Ireland and the United Kingdom for the majority of his successful career. Dr. Farrell's tenure at Eli Lilly included positions of Managing Director, leading the commercial sales and marketing in Ireland where he launched several major products in Europe; Director Strategy, Commercial and Business in the UK accountable for long-term strategic planning and business operations as well as other positions related to compliance, production, sales, and planning.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.